miRNAs role in bladder cancer pathogenesis and targeted therapy: Signaling pathways interplay – A review

El-Mahdy, Hesham A.; Elsakka, Elsayed G.E.; El-Husseiny, Ahmed A.; Ismail, Ahmed; Yehia, Amr Mohamed; Abdelmaksoud, Nourhan M.; Elshimy, Reham A A; Noshy, Mina; Doghish, Ahmed S.

doi:10.1016/j.prp.2023.154316

Cited by 57 publications

(3 citation statements)

References 201 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Signaling pathways often involve specific biomarkers that can indicate disease presence, progression, or response to treatment. By understanding the signaling events 1 Idelalisib is a kinase inhibitor. Designed to target and inhibit a certain enzyme called phosphoinositide 3-kinase (PI3K).…”

Section: Biomarker Discoverymentioning

confidence: 99%

“…The importance of signaling pathways in drug development lies in their involvement in a variety of diseases. Dysregulation or improper activation of these signaling pathways is commonly associated with the development and progression of numerous diseases, including cancer, diabetes, cardiovascular disease, and neurological disorders [1]. Understanding the molecular intricacies of these signaling networks enables researchers to identify critical therapeutic targets and design novel drugs aimed at the precise modulation of specific signaling pathways.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Signaling Pathways in Drug Development

Ali Ahmad,

Seemab,

Wahab

et al. 2024

Drug Development and Safety

View full text Add to dashboard Cite

This chapter reviews the basic principles of signal transduction and highlights its critical role in drug discovery and development. The chapter begins by explaining the concept of cellular signaling and the variety of signaling pathways that regulate critical cellular processes. It examines the key components of signaling pathways, including receptors, ligands, intercellular messengers, and effectors, and emphasizes their complex interplay. In addition, the chapter examines the role of signaling pathways as targets for drug interventions. It examines different classes of receptors, such as G protein-coupled receptors, nuclear receptors, and tyrosine kinase receptors, and discusses their activation and downstream signaling events. The various mechanisms of drug action, including agonists, antagonists, and modulators, are also studied in the context of signal transduction. In addition, the chapter highlights the importance of pathway specificity and crosstalk in drug development and highlights the challenges and opportunities associated with pharmacological modulation of pathways. It also addresses the impact of dysregulated signaling pathways in disease, and how targeted use of these pathways can lead to innovative therapeutic strategies. Finally, the chapter addresses the importance of studying signal transduction in both preclinical and clinical settings, emphasizing the need for robust and reliable tests to assess drug efficacy and safety and for effective use of therapeutics.

show abstract

Section: Biomarker Discoverymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Signaling Pathways in Drug Development

Ali Ahmad,

Seemab,

Wahab

et al. 2024

Drug Development and Safety

View full text Add to dashboard Cite

show abstract

“…Noncoding RNAs (ncRNAs) are RNA transcripts that encode noncoding sequences of the human genome and are divided into particular types related to their length and structure. It is now well documented that ncRNAs including long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) can influence many processes that contribute to multiple diseases, including cancers (5,6), liver diseases (7,8), bone diseases (9,10), multiple myeloma (11,12), cardiovascular diseases (13,14), rheumatoid arthritis (15,16), diabetes (17,18), obesity and metabolic syndrome (19,20) .…”

Section: Introductionmentioning

confidence: 99%

The crucial role of long non-coding RNAs in the pathogenesis, therapeutic response, and clinical implications of esophageal cancer

El-Husseiny,

Ali,

Fakhry

2024

ERU Research Journal

View full text Add to dashboard Cite

Esophageal cancer (EC) is the 2nd fatal gastrointestinal tract malignancy and the sixth most predominant driver of cancer-associated mortality worldwide. Interestingly, long non-coding RNAs (lncRNAs) have a sequence of more than 200 base pairs and are regarded as one of the epigenetic elements. LncRNAs have been demonstrated to influence EC features comprising initiation, development, angiogenesis, invasion, and metastasis. Notably, lncRNAs could modulate the expression of several genes and chromatin architectures which are implicated in EC pathogenesis.Besides, numerous lncRNAs have a crucial role in the chemotherapeutic response of EC cells.Furthermore, lncRNAs are thought to be a promising biomarker in EC whose expression patterns can distinguish between EC subtypes and stages as well as predict cancer aggressiveness. Thus, the ERURJ 2024, x, x, 1-27, accepted 2 current review emphasizes the latest updates on the modulatory functions of lncRNAs in EC pathogenesis, their significance to the EC cells' therapeutic response, and their clinical efficacy as prognostic and diagnostic biomarkers.

show abstract